Shenzhen Zhongge Biotechnology Co. Ltd. has identified translation initiation factor 2B (EIF2B) activators reported to be useful for the treatment of autoimmune disease, cancer, viral infection, neurodegeneration, metabolic diseases, and eye, dermatological and inflammatory disorders, among others.